GD-11(GD-11) - 在研适应症：急性缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

神经系统疾病心血管疾病

在研适应症

急性缺血性卒中

非在研适应症-

原研机构

江苏万高药业股份有限公司

在研机构

江苏万高药业股份有限公司

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构

分子式C18H35NO2

InChIKeyCUPZOFRJARGVBC-UHFFFAOYSA-N

CAS号34256-92-3

关联

6

项与 GD-11 相关的临床试验

NCT06299579 / Recruiting临床3期IIT

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment.

开始日期2024-02-29

申办/合作机构

江苏万高药业股份有限公司

ChiCTR2400080972 / Suspended临床3期IIT

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study

开始日期2024-02-19

申办/合作机构-

CTR20222803 / Recruiting临床2期

注射用 GD-11 治疗急性缺血性卒中 II 期临床试验——随机、平行、对照 II 期临床研究

探索注射用GD-11不同剂量治疗发病在48h以内的急性缺血性卒中患者的有效性和安全性

开始日期2022-11-17

申办/合作机构

江苏万高药业股份有限公司

100 项与 GD-11 相关的临床结果

登录后查看更多信息

100 项与 GD-11 相关的转化医学

登录后查看更多信息

100 项与 GD-11 相关的专利（医药）

登录后查看更多信息

10

项与 GD-11 相关的文献（医药）

2024-08-01·Chemistry & Biodiversity

Graphiumisides A–D, Monoterpene Glycosides from an Animal‐Derived Endophytic Fungus Graphium sp. GD‐11

Article

作者: Wang, Xiaowei ; Ji, Mengshan ; Guo, Tao ; Wei, Wenjun ; Li, Dongyang ; Zhang, Mingyue ; Zhang, Yuhang ; Wang, Haibo ; Hui, Chengcheng

AbstractFour new monoterpene rhamnosides, graphiumisides A–D (1–4), along with four known steroid compounds (5–8) were isolated from the fermentation extract of animal‐derived endophytic fungus, Graphium sp. GD‐11. The chemical structures of all compounds were elucidated using 1D and 2D NMR, HRESIMS spectroscopic analyses, and other spectroscopic methods. Compounds 1–4 exhibit a distinctive structure connected by one p‐menthane type monoterpene and one L‐rhamnose. This is the first report of monoterpene glycosides from Graphium sp. All compounds (1–8) were tested for cytotoxic activities against four cancer cell lines (HepG2, SMMC7721, SW480, and A549), and only compound 1 showed weak anti‐tumor activity against SMMC7721 cells.

2014-11-01·Archives of Virology4区 · 医学

Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs

4区 · 医学

Article

作者: Meng Huang ; Hai Yu ; Sheng Yang ; Ze-Jun Li ; Fu-ru Yang ; Feng Wen ; Yan-Jun Zhou ; Guang-Zhi Tong

Swine influenza (SI) is an acute, highly contagious respiratory disease caused by swine influenza A viruses (SwIVs), and it poses a potential global threat to human health. Classical H1N1 (cH1N1) SwIVs are still circulating and remain the predominant subtype in the swine population in China. In this study, a high-growth reassortant virus (GD/PR8) harboring the hemagglutinin (HA) and neuraminidase (NA) genes from a novel cH1N1 isolate in China, A/Swine/Guangdong/1/2011 (GD/11) and six internal genes from the high-growth A/Puerto Rico/8/34(PR8) virus was generated by plasmid-based reverse genetics and tested as a candidate seed virus for the preparation of an inactivated vaccine. The protective efficacy of this vaccine was evaluated in mice and pigs challenged with GD/11 virus. Prime and boost inoculation of GD/PR8 vaccine yielded high-titer serum hemagglutination inhibiting (HI) antibodies and IgG antibodies for GD/11 in both mice and pigs. Complete protection of mice and pigs against cH1N1 SIV challenge was observed, with significantly fewer lung lesions and reduced viral shedding in vaccine-inoculated animals compared with unvaccinated control animals. Our data demonstrated that the GD/PR8 may serve as the seed virus for a promising SwIVs vaccine to protect the swine population.

2014-09-14·Biofouling3区 · 生物学

Antimicrobial and anti-biofilm effect of a novel BODIPY photosensitizer againstPseudomonas aeruginosaPAO1

3区 · 生物学

Article

作者: Morten Rybtke ; Stefano Banfi ; Tim Tolker-Nielsen ; Paola Barbieri ; Enrico Caruso ; Viviana Teresa Orlandi

Photodynamic therapy (PDT) combines the use of organic dyes (photosensitizers, PSs) and visible light in order to elicit a photo-oxidative stress which causes bacterial death. GD11, a recently synthesized PS belonging to the boron-dipyrromethene (BODIPY) class, was demonstrated to be efficient against planktonic cultures of Pseudomonas aeruginosa, causing a 7 log unit reduction of viable cells when administered at 2.5 μM. The effectiveness of GD11 against P. aeruginosa biofilms grown in flow-cells and microtiter trays was also demonstrated. Confocal laser scanning microscopy of flow-cell-grown biofilms suggests that the treatment has a biocidal effect against bacterial biofilm cells.

100 项与 GD-11 相关的药物交易

登录后查看更多信息